We will soon know how the FDA pathway to emergency use is progressing. I had a look at the FDA EUA's last night and whilst there are many applications regarding devices, etc, there is not much showing for treatment. If we get EU approval from the FDA, Europe will follow and 675 will be commercialised for the use on covid patients. I think, but dont hold me to it, $15 k per course, so do the maths. Its going to make our quarterlys look pretty robust and would delay or diminish any need for any CR in the future. As mentioned before, this stock is on the launch pad and the countdown is ticking.
IHL Price at posting:
21.0¢ Sentiment: Buy Disclosure: Held
